Literature DB >> 29923861

Optimized Protocol for Regeneration of the Conjunctival Epithelium Using the Cell Suspension Technique.

Marina Bertolin1, Claudia Breda1, Stefano Ferrari1, Sara Ilse Van Acker2, Nadia Zakaria2,3, Enzo Di Iorio1,4, Angelo Migliorati4, Diego Ponzin1, Barbara Ferrari1, Zala Lužnik5, Vanessa Barbaro1.   

Abstract

PURPOSE: To develop autologous tissue-engineered conjunctival epithelial sheets to be used as advanced therapy medicinal products for severe ocular surface disorders involving the conjunctiva.
METHODS: Methods used aimed at 1) mapping the conjunctiva for identification of the stem cell location, 2) establishing proper cell culturing conditions, 3) identifying the proper scaffold, and 4) characterizing the conjunctival grafts better. For these purposes, immunostaining and PAS staining, serial cultivation of cells, and quantitative polymerase chain reaction ([INCREMENT]Np63α and MUC5AC) were performed.
RESULTS: The inferior fornix represents the ideal area where to take the conjunctival biopsies from, with at least +3.58% of clonogenic colonies and higher percentages of stem cells compared with other areas, as confirmed by [INCREMENT]Np63α expression levels (6.79% ± 1.18%). The standard culture conditions are necessary when cells are cultured on bare plastic, while animal-free media can be used for conjunctival cell culture on the scaffold. Fibrin glue represents the ideal scaffold for production of epithelial conjunctival grafts because it allows physiological expression of the main conjunctival cell markers, with K19 as the ideal one (98.5% ± 0.5% positive cells). The presence of goblet cells (6.3% ± 1.3%) and expression of the stem cell marker [INCREMENT]Np63α (1.65% ± 0.35% positive cells) were also assessed.
CONCLUSIONS: Our findings pave the way for ex vivo cultivation of conjunctival epithelial cells onto a scaffold using the cell suspension technique by means of animal-free media. This would allow us to obtain conjunctival grafts for clinical purposes, thus giving a therapeutic option to patients with conjunctival diseases refractory to current therapies.

Entities:  

Mesh:

Year:  2019        PMID: 29923861     DOI: 10.1097/ICO.0000000000001670

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

Review 1.  Conjunctival goblet cells: Ocular surface functions, disorders that affect them, and the potential for their regeneration.

Authors:  Shivalingappa K Swamynathan; Alan Wells
Journal:  Ocul Surf       Date:  2019-11-14       Impact factor: 5.033

2.  Autologous simple conjunctival epithelial transplantation for primary pterygium.

Authors:  Emilio Pedrotti; Marina Bertolin; Adriano Fasolo; Erika Bonacci; Francesca Bosello; Diego Ponzin; Giorgio Marchini
Journal:  Int Ophthalmol       Date:  2022-05-25       Impact factor: 2.031

3.  Analysis and pharmacological modulation of senescence in human epithelial stem cells.

Authors:  Vanessa Barbaro; Antonio Orvieto; Gualtiero Alvisi; Marina Bertolin; Filippo Bonelli; Thomas Liehr; Tigran Harutyunyan; Stefanie Kankel; Gordana Joksic; Stefano Ferrari; Elena Daniele; Diego Ponzin; Daniela Bettio; Leonardo Salviati; Enzo Di Iorio
Journal:  J Cell Mol Med       Date:  2022-06-15       Impact factor: 5.295

4.  Rapid bioprinting of conjunctival stem cell micro-constructs for subconjunctival ocular injection.

Authors:  Zheng Zhong; Xiaoqian Deng; Pengrui Wang; Claire Yu; Wisarut Kiratitanaporn; Xiaokang Wu; Jacob Schimelman; Min Tang; Alis Balayan; Emmie Yao; Jing Tian; Luwen Chen; Kang Zhang; Shaochen Chen
Journal:  Biomaterials       Date:  2020-10-23       Impact factor: 12.479

Review 5.  Human ocular mucins: The endowed guardians of sight.

Authors:  Pablo Argüeso
Journal:  Adv Drug Deliv Rev       Date:  2021-12-04       Impact factor: 15.470

Review 6.  The Communication between Ocular Surface and Nasal Epithelia in 3D Cell Culture Technology for Translational Research: A Narrative Review.

Authors:  Malik Aydin; Jana Dietrich; Joana Witt; Maximiliane S C Finkbeiner; Jonas J-H Park; Stefan Wirth; Christine E Engeland; Friedrich Paulsen; Anja Ehrhardt
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.